These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 3874911

  • 1. The mechanism of tumor growth inhibition by tumor-specific Lyt-1+2-T cells. I. Antitumor effect of Lyt-1+2-T cells depends on the existence of adherent cells.
    Fujiwara H, Takai Y, Sakamoto K, Hamaoka T.
    J Immunol; 1985 Sep; 135(3):2187-91. PubMed ID: 3874911
    [Abstract] [Full Text] [Related]

  • 2. Requirements of adherent cells for activating Lyt-1+2- T cells as well as for functioning as antitumor effectors activated by factor(s) from Lyt-1+2- T cells.
    Sakamoto K, Fujiwara H, Nakajima H, Yoshioka T, Takai Y, Hamaoka T.
    Jpn J Cancer Res; 1986 Nov; 77(11):1142-52. PubMed ID: 3098724
    [Abstract] [Full Text] [Related]

  • 3. Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.
    Nakajima H, Fujiwara H, Takai Y, Izumi Y, Sano S, Tsuchida T, Hamaoka T.
    J Immunol; 1985 Sep; 135(3):2199-205. PubMed ID: 3894520
    [Abstract] [Full Text] [Related]

  • 4. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
    Fujiwara H, Fukuzawa M, Yoshioka T, Nakajima H, Hamaoka T.
    J Immunol; 1984 Sep; 133(3):1671-6. PubMed ID: 6205091
    [Abstract] [Full Text] [Related]

  • 5. Demonstration of intratumoral infiltration of tumor-specific Lyt-1+2- T cells mediating delayed-type hypersensitivity response and in vivo protective immunity.
    Tomita S, Fujiwara H, Yamane Y, Sano S, Nakajima H, Izumi Y, Arai H, Kawanishi Y, Tsuchida T, Hamaoka T.
    Jpn J Cancer Res; 1986 Feb; 77(2):182-9. PubMed ID: 3082830
    [Abstract] [Full Text] [Related]

  • 6. Augmentation of antitumor immune response by trinitrophenyl (TNP)-reactive helper T-cells: enhanced induction of tumor-specific Lyt-1+2- T-cell-mediated delayed-type hypersensitivity from spleen cells of tumor-bearing mice by TNP helpers.
    Suda T, Fujiwara H, Mizushima Y, Shearer GM, Hamaoka T.
    J Natl Cancer Inst; 1986 Dec; 77(6):1267-72. PubMed ID: 2948049
    [Abstract] [Full Text] [Related]

  • 7. Enhanced induction of tumor-specific Lyt-1+2- T cell-mediated protective immunity by in vivo administration of interleukin 1.
    Izumi Y, Tsuchida T, Okuno K, Fujiwara H, Hamaoka T.
    Jpn J Cancer Res; 1985 Sep; 76(9):863-70. PubMed ID: 3932286
    [Abstract] [Full Text] [Related]

  • 8. Mechanisms for recognition of tumor antigens and mediation of anti-tumor effect by noncytolytic Lyt-2+ T cell subset.
    Sakamoto K, Yoshioka T, Shimizu J, Sato S, Nakajima H, Fujiwara H, Hamaoka T.
    Jpn J Cancer Res; 1988 Jan; 79(1):99-108. PubMed ID: 3128511
    [Abstract] [Full Text] [Related]

  • 9. The role of anti-asialo GM1 antibody-sensitive cells in the implementation of tumor-specific T cell-mediated immunity in vivo.
    Yoshioka T, Sato S, Fujiwara H, Hamaoka T.
    Jpn J Cancer Res; 1986 Aug; 77(8):825-32. PubMed ID: 3093429
    [Abstract] [Full Text] [Related]

  • 10. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
    Mokyr MB, Ye QW.
    Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
    [Abstract] [Full Text] [Related]

  • 11. Evidence for cytostatic T cell activity in the effector mechanism against syngeneic TMT mammary tumor cells in mice.
    Kurata S, Tsuchiya T, Norimura T, Yamashita U.
    J Immunol; 1983 Jan; 130(1):496-500. PubMed ID: 6600195
    [Abstract] [Full Text] [Related]

  • 12. Cellular interactions and the role of interleukin 2 in the expression and induction of immunity against a syngeneic murine sarcoma.
    Chou T, Shu S.
    J Immunol; 1987 Sep 15; 139(6):2103-9. PubMed ID: 2957448
    [Abstract] [Full Text] [Related]

  • 13. Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses.
    Fujiwara H, Yoshioka T, Shima J, Kosugi A, Itoh K, Hamaoka T.
    J Immunol; 1986 Apr 01; 136(7):2715-9. PubMed ID: 3005417
    [Abstract] [Full Text] [Related]

  • 14. Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells.
    Barker E, Mokyr MB.
    Cancer Res; 1988 Sep 01; 48(17):4834-42. PubMed ID: 3261626
    [Abstract] [Full Text] [Related]

  • 15. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. II. Lyt-1+2- T cells have potential to reject antigenically irrelevant (bystander) tumor cells on activation with the specific target tumor cells.
    Yoshioka T, Fujiwara H, Takai Y, Ogata M, Shimizu J, Hamaoka T.
    Cancer Immunol Immunother; 1987 Sep 01; 24(1):8-12. PubMed ID: 3493074
    [Abstract] [Full Text] [Related]

  • 16. Significance of suppressor macrophages for immunosurveillance of tumor-bearing mice.
    Fujii T, Igarashi T, Kishimoto S.
    J Natl Cancer Inst; 1987 Mar 01; 78(3):509-17. PubMed ID: 2950265
    [Abstract] [Full Text] [Related]

  • 17. Lysis of antigenically unrelated tumor cells mediated by Lyt 2+ splenic T-cells from melphalan-cured MOPC-315 tumor bearers.
    Barker E, Wise JA, Dray S, Mokyr MB.
    Cancer Res; 1989 Sep 15; 49(18):5007-15. PubMed ID: 2788494
    [Abstract] [Full Text] [Related]

  • 18. Enrichment of antitumor effector cells that are effective in vivo from spleen cells of tumor-bearing mice through the use of Dolichos biflorus lectin.
    Okada T, Ezawa K, Imai Y, Osawa T.
    Cancer Res; 1986 Nov 15; 46(11):5611-7. PubMed ID: 3093067
    [Abstract] [Full Text] [Related]

  • 19. Contrasuppressor cells that break oral tolerance are antigen-specific T cells distinct from T helper (L3T4+), T suppressor (Lyt-2+), and B cells.
    Kitamura K, Kiyono H, Fujihashi K, Eldridge JH, Green DR, McGhee JR.
    J Immunol; 1987 Nov 15; 139(10):3251-9. PubMed ID: 3500210
    [Abstract] [Full Text] [Related]

  • 20. Murine tumor cell lysis by antibody-dependent macrophage-mediated cytotoxicity using syngeneic monoclonal antibodies.
    Kawase I, Komuta K, Ogura T, Fujiwara H, Hamaoka T, Kishimoto S.
    Cancer Res; 1985 Apr 15; 45(4):1663-8. PubMed ID: 3978634
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.